ABN202 (αEGFR) / Abion, Genopharm - LARVOL DELTA

ABN202 (antibody-interferon-β mutein), a potent antibody-cyokine fusion protein platform for the treatment of various solid tumors (SITC 2024) - "In ADC resistance pre-clinical models, ABN202 showed superior anti-cancer efficacy compared to other ADCs. Conclusions We concluded that ABN202 is a promising drug candidate for various solid cancers, serving as a platform technology beyond antibody-drug conjugates."

Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR • IFNAR1 • IFNB1 • MSLN

Abion Announces Anticancer Efficacy of Next-Generation Platform ’ABN202’ at SITC [Google translation] (Pharm News) - "Abion announced on the 14th that it will participate in the '2024 Society for Immunotherapy of Cancer (SITC)' to be held in Houston, Texas, USA from the 6th to the 10th of next month (local time)...Abion will present at the conference the excellent anticancer effects of ABN202, an antibody cytokine fusion protein (ACFP) platform that fuses an interferon beta variant to a tumor-targeting antibody, in various solid tumor non-clinical models...The company also plans to release non-clinical data confirming excellent immune anticancer efficacy in an immunosuppressive solid tumor mouse model. Based on this, it explained that there is a high possibility that it will be used as a combination therapy with immune checkpoint inhibitors."

Preclinical • Oncology • Solid Tumor

Abion unveils phase 2 cut-off results for vabametkib and combination strategy with lazertinib at ASCO 2024 (Korea Biomedical Review) - "In addition to vabametkib, Abion presented the clinical design for a combination therapy involving vabametkib and Johnson & Johnson’s lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The first patient enrollment is anticipated in the fourth quarter of this year....Abion also introduced ABN501, the only existing Claudin-3 protein antibody, currently in the preclinical stage and under a joint research partnership with the National Cancer Institute (NCI)...An investigational new drug (IND) application for ABN501 is planned for submission in the second half of next year. In addition, Abion showcased its novel antibody-cytokine fusion protein (ACFP) platform technology, ABN 202."

IND • New trial • Preclinical • Oncology • Solid Tumor

ABN202 (anti-Trop-2-interferon-beta mutein): A potent antibody-cytokine fusion protein for the treatment of Trop-2 positive solid tumors (AACR 2024) - "In conclusion, ABN202 (αTrop-2) demonstrated potent anti-cancer efficacy compared to Trodelvy®. Our results support ABN202 (αTrop-2) as a promising drug candidate against Trop2-positive solid tumors."

Biliary Cancer • Bladder Cancer • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • IFNB1 • TACSTD2

[ET Lasciro] Telcon RF Pharmaceutical becomes Abion’s largest shareholder… Stock price rises together [Google translation] (ET news) - "Telcon RF Pharmaceuticals purchased additional Abion common stocks through a block deal (after-hours bulk trading) on ​​this day, and now holds a total of 4,486,274 shares (20.37% stake)...A Telcon RF Pharmaceutical official said, 'We decided to acquire additional shares because we judged that the possibility of a large-scale technology transfer contract for ABN401 (c-MET targeting anticancer drug), Abion’s main pipeline, was becoming visible,'....'In addition to ABN401, we will secure various technologies and maximize synergies, including the next-generation platform technology ‘ABN202’, which is being developed based on ACFP (antibody-cytokine fusion protein) platform technology.'"

Licensing / partnership • Oncology • Solid Tumor

Potent anti-tumor activity of ABN202 (anti-EGFR antibody-interferon-beta mutein) through direct cytotoxicity and indirect immune activation against non-small cell lung cancer, regardless of EGFR mutation status (AACR 2024) - "In a previous study, we designed ABN202 (αEGFR) to comprise an EGFR targeting antibody (Cetuximab) and IFN-β mutein (ABN102) and we confirmed anti-cancer activities of ABN202 against EGFR-positive NSCLC. ABN202 (αEGFR) demonstrates potent anti-tumor activity through direct cytotoxicity and indirect immune activation in NSCLC, regardless of EGFR mutation status. Taken together, we suggest that ABN202 (αEGFR) is a promising drug candidate against NSCLC, regardless of EGFR mutation status."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNAR1 • IFNB1

Abion's Next-Generation Technology, 'ABN202', Follows 'Babamekip' [Google translation] (Abion Press Release) - "Abion will present research results related to three types of ABN202 technologies at the AACR held in April. These are anti-TROP2, anti-EGFR, and anti-VISTA·MSLN substances utilizing the ABN202 platform....In in vitro and in vivo experiments, ABN202 (αTROP-2) showed anticancer activity in TROP2-positive triple-negative breast cancer, bile duct cancer, and bladder cancer. Cell line analysis was also conducted to identify ABN202 response biomarkers."

Preclinical • Bladder Cancer • Breast Cancer • Cholangiocarcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

ABN202 (αEGFR-interferon-β mutein), a potent antibody-cytokine fusion protein for the treatment of EGFR-positive non-small cell lung cancer (AACR 2023) - "Taken together, we suggest that ABN202 has potent anti-cancer activities, via direct cytotoxicity in EGFR-positive tumors and indirectly activating immune cells through Type I IFN signaling. we conclude ABN202 is a promising drug candidate for patients with EGFR-positive NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • IFNAR2 • IFNB1

Sacituzumab-Interferon beta mutein fusion protein, ABN202 (anti Trop2-interferon beta mutein), is a potent therapeutics for Trop-2-positive urothelial cancer (AACR 2023) - "Recently, Trop2 targeting antibody-drug conjugate such as sacituzumab-govitecan (Trodelvy®) was approved for the treatment of triple-negative breast cancer and urothelial cancer (UC) patients. The anti-cancer efficacy of ABN202 were confirmed in Trop2-positive tumor mouse model.Conclusion : We evaluated the direct and indirect anti-cancer efficacy of ABN202 (anti Trop2-interferon-beta mutein) in Trop2-positive urothelial cancer. Our results support that ABN202 is a potent drug candidate in Trop2-positive urothelial cancer by directly inhibiting tumor growth and activating anti-cancer immune responses through type 1 IFN signaling."

Breast Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • TACSTD2